Aducanumab Fall-Out: An Inexpedient Use Of ‘Expedited’ Review

 
• By Michael McCaughan

The aducanumab review involved everything sponsors might think they could want from the US FDA, with the agency taking a hands on approach to expedite a complex and difficult review in hopes of delivering an important new therapy to patients as quickly as possible. Unfortunately, in this case, FDA seems to have expedited the review right over a cliff.

Express delivery van jumps over cliff
The US FDA chose the most direct route to deliver the Biogen Alzheimer’s candidate to market, but it might not make it. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers